Celcuity's High-Stakes Oncology Bet Is Underappreciated
Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...
pharmaphorum2d
Lilly nets Scorpion cancer drug in $2.5bn licensing deal
That could make it easier to tolerate, with fewer off-target side effects, than current drugs in the class. The first PI3K inhibitor to reach the US market for a breast cancer indication was ...
Cure Today2d
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
eLife4d
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape
Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.
Yahoo Finance4d
Celcuity Inc. (CELC)
After hours: February 18 at 4:20:00 PM EST Loading Chart for CELC ...